June 17, 2022
Life Sciences
  • The Federal Trade Commission (FTC) released a policy statement that it plans to “ramp up enforcement” on the prescription drug industry over illegal rebates and other fees that inhibit patients’ access to lower-cost medicines. The FTC, which previously indicated that it would investigate pharmacy benefit managers, highlighted in its statement the 300 percent price jump for insulin over the past two decades as an example. (Article here)